As these medications come in injectable form, they are administered as a once weekly injection under the skin (subcutaneously) in the belly, outer thighs, upper buttocks, or the back of the arms
Therefore, taking a dose less than the recommended one may not provide optimal results
55 In regard to their safety profile, small molecule GLP-1 RAs have also shown similar side effects, being the gastrointestinal symptoms such as nausea, vomiting, and diarrhea the most commonly presented
Conversion charts between semaglutide and tirzepatide exist to help guide these transitions
Researchers believe this added pathway may help explain the strong weight loss results seen in early studies
placebo, STEP trials) demonstrate GLP-1 agonists produce significantly greater weight loss and cardiovascular benefits than behavior modification alone